Journal of Psychoactive Drugs
September 1, 2021
Alan K. Davis, Gabrielle Agin-Liebes, Megan España et al.
103 citations
Psychologists are a vital component of mental health treatment and their perceptions of psychedelic-assisted therapy are critical for future implementation. This cross-sectional quasi-experimental electronic survey study explored the attitudes about psychedelics used in treatment among 366 clinical psychologists in the United States. Participants expressed cautiously favorable attitudes toward...
Harm Reduction Journal
April 11, 2021
Brian Pilecki, Jason B. Luoma, Geoff J. Bathje et al.
135 citations
Abstract Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own...
Journal of Psychoactive Drugs
June 12, 2020
Jason B. Luoma, Christina Chwyl, Geoff J. Bathje et al.
206 citations
After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted therapy for mental health conditions have begun to be published. We identified nine randomized, placebo-controlled clinical trials of psychedelic-assisted therapy published since 1994. Studies examined psilocybin, LSD (lysergic acid diethylamide),...
Jason B. Luoma, M. Kati Lear, Kyong Yi et al.
preprint
This case report describes the application of in vivo and imaginal exposure techniqueswithin MDMA-assisted therapy (MDMA-AT) for social anxiety disorder (SAD). The treatment,conducted as part of a randomized controlled trial, consisted of three non-drug preparationsessions, two drug sessions, and six non-drug integration sessions. Exposure interventionsincluded imaginal exposure to...
Guy Simon, Nir Tadmor, Jules Evans et al.
preprint
Abstract Background Psychedelic substances are increasingly used outside clinical trials, yet individuals seeking support after challenging experiences often report that available services are inadequate or misaligned with their needs. While prior research documents both beneficial and adverse outcomes of naturalistic use, less is known about how such experiences are received and interpreted...